[Clinical use of podophyllinic acid ethylhydrazide (SP-I) and podophyllotoxin-beta-o-benzyliden-glucoside (SP-G) in malignant urologic tumors].
D000328:Adult; D000368:Aged; D055598:Chemical Phenomena; D002621:Chemistry; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011033:Podophyllin / Q000009:adverse effects / Q000627:therapeutic use; D011035:Podophyllum / Q000627:therapeutic use*; D014565:Urogenital Neoplasms / Q000188:drug therapy*
D011033:Podophyllin